WO2003064458A8 - Derives peptidiques, leur preparation et leur application therapeutique et cosmetique - Google Patents

Derives peptidiques, leur preparation et leur application therapeutique et cosmetique

Info

Publication number
WO2003064458A8
WO2003064458A8 PCT/FR2003/000300 FR0300300W WO03064458A8 WO 2003064458 A8 WO2003064458 A8 WO 2003064458A8 FR 0300300 W FR0300300 W FR 0300300W WO 03064458 A8 WO03064458 A8 WO 03064458A8
Authority
WO
WIPO (PCT)
Prior art keywords
group
chosen
amino acid
preparation
natural amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/000300
Other languages
English (en)
Other versions
WO2003064458A2 (fr
WO2003064458A3 (fr
Inventor
Anne-Marie Pinel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Europeen de Biologie Cellulaire
Original Assignee
Institut Europeen de Biologie Cellulaire
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003064458(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP20030717360 priority Critical patent/EP1470157A2/fr
Priority to US10/503,090 priority patent/US7268108B2/en
Priority to AU2003222347A priority patent/AU2003222347A1/en
Priority to JP2003564078A priority patent/JP4237067B2/ja
Priority to CA002474719A priority patent/CA2474719A1/fr
Application filed by Institut Europeen de Biologie Cellulaire filed Critical Institut Europeen de Biologie Cellulaire
Priority to KR10-2004-7011955A priority patent/KR20040105709A/ko
Publication of WO2003064458A2 publication Critical patent/WO2003064458A2/fr
Publication of WO2003064458A3 publication Critical patent/WO2003064458A3/fr
Anticipated expiration legal-status Critical
Publication of WO2003064458A8 publication Critical patent/WO2003064458A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des Peptide répondant à la formule (1) R-V l-Ala2-His3-X4-Y5-Trp 5-NH2 (1) dans laquelle R représente un atome d'hydrogène ou un groupe protecteur pouvant être choisi parmi un groupe acétyle, un groupe benzoyle, un groupe tosyle, un groupe benzène sulfonyle, un groupe benzyloxycarbonyle ou un groupe pyridinepropionyle; V représente un acide aminé naturel ou non choisi parmi la norleucine, la norvaline et la 2-N-Me-norleucine, X représente un acide aminé naturel ou non à caractère aromatique choisi parmi phénylalanine, 1-naphtylalanine, 2-naphtylalanine, phénylglycine, benzothiénylalanine, 4,4'-biphénylalanine, 3,3-diphénylalanine, homophénylalanine, indanylglycine, 4-méthylphénylalanine, thiénylalanine, p-nitrophénylalanine, halogénophénylalanine de configuration L ou D; Y représente un acide aminé naturel de configuration L, à caractère basique choisi parmi arginine, lysine ou ornithine, leurs énantiomères ou diastéréoisomères, ainsi que leurs mélanges, y compris les mélanges racémiques. Procédé de préparation et application en thérapeutique et en cosmétique.
PCT/FR2003/000300 2002-02-01 2003-01-31 Derives peptidiques, leur preparation et leur application therapeutique et cosmetique Ceased WO2003064458A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR10-2004-7011955A KR20040105709A (ko) 2002-02-01 2003-01-31 신규한 펩티드 유도체, 이의 제제와 치료 및 미용학적 응용
US10/503,090 US7268108B2 (en) 2002-02-01 2003-01-31 Alpha-melanocyte stimulating hormone derivatives and cosmetic application thereof
AU2003222347A AU2003222347A1 (en) 2002-02-01 2003-01-31 Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof
JP2003564078A JP4237067B2 (ja) 2002-02-01 2003-01-31 新規なペプチド誘導体、その製造、ならびにその治療的および化粧的用途
CA002474719A CA2474719A1 (fr) 2002-02-01 2003-01-31 Derives peptidiques, leur preparation et leur application therapeutique et cosmetique
EP20030717360 EP1470157A2 (fr) 2002-02-01 2003-01-31 Derives peptidiques, leur preparation et leur application therapeutique et cosmetique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/01202 2002-02-01
FR0201202A FR2835528B1 (fr) 2002-02-01 2002-02-01 Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique

Publications (3)

Publication Number Publication Date
WO2003064458A2 WO2003064458A2 (fr) 2003-08-07
WO2003064458A3 WO2003064458A3 (fr) 2004-03-25
WO2003064458A8 true WO2003064458A8 (fr) 2005-04-07

Family

ID=27619816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000300 Ceased WO2003064458A2 (fr) 2002-02-01 2003-01-31 Derives peptidiques, leur preparation et leur application therapeutique et cosmetique

Country Status (8)

Country Link
US (1) US7268108B2 (fr)
EP (1) EP1470157A2 (fr)
JP (1) JP4237067B2 (fr)
KR (1) KR20040105709A (fr)
AU (1) AU2003222347A1 (fr)
CA (1) CA2474719A1 (fr)
FR (1) FR2835528B1 (fr)
WO (1) WO2003064458A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453219B2 (en) * 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
FR2870244B1 (fr) * 2004-05-11 2011-01-07 Centre Nat Rech Scient Conjugues dipeptidiques antagonistes de l'alpha-msh
FR2870242B1 (fr) * 2004-05-11 2010-08-20 Inst Europeen Biologie Cellulaire Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie.
FR2870243B1 (fr) * 2004-05-11 2010-11-19 Centre Nat Rech Scient Conjugues tripeptidiques agonistes de la msh
TWI415628B (zh) 2006-02-28 2013-11-21 Avon Prod Inc 包含具有非天然胺基酸之胜肽之組合物及其使用方法
US8481006B2 (en) * 2008-04-25 2013-07-09 New Sunshine, Llc Melt formula
US20090269375A1 (en) * 2008-04-25 2009-10-29 Diahne Patnode Tanning compositions containing juice concentrate
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
WO2009151383A1 (fr) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Peptides spécifiques des récepteurs de la mélanocortine pour le traitement de l’obésité et d’autres pathologies associées à la fonction des récepteurs de la mélanocortine
JP2011195451A (ja) * 2008-06-20 2011-10-06 Fukuoka Univ ペプチド
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (fr) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
CA2761607C (fr) 2009-06-08 2018-09-04 Yi-Qun Shi Peptides specifiques du recepteur de la melanocortine
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
US9290539B2 (en) 2011-05-17 2016-03-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanotropin ligands for skin care
WO2012158960A2 (fr) 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Ligands du récepteur à la mélanocortine de type 1 et leurs procédés d'utilisation
FR3004927B1 (fr) * 2013-04-29 2016-08-05 Oreal Composition comprenant au moins trois actifs pour colorer et/ou pigmenter les matieres keratiniques.
KR101713127B1 (ko) * 2014-05-13 2017-03-10 (주)케어젠 저색소증 개선 및 지방 형성 억제 효능을 갖는 펩타이드 및 이의 용도
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
EP3088417A1 (fr) * 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Composé pharmaceutique
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
JP6541118B1 (ja) * 2018-04-27 2019-07-10 株式会社成和化成 化粧品基材および該化粧品基材を含有する毛髪用化粧品、美白剤
TWI742389B (zh) * 2019-06-21 2021-10-11 和和實業股份有限公司 促進黑色素生成的胜肽及其方法
FR3112478B1 (fr) 2020-07-15 2022-12-02 France Cosmephyl Lab Nouvelles compositions associant des dérivés de chanvre et au moins un peptide et leur utilisation
CN113876622A (zh) * 2021-11-08 2022-01-04 广东重生药业科技有限公司 一种极光精华水及其制备方法
FR3134519B1 (fr) 2022-04-14 2025-07-25 France Cosmephyl Lab Nouvelles compositions associant au moins un filtre solaire inorganique et leur utilisation
EP4292581A1 (fr) 2022-06-16 2023-12-20 Bella Aurora Labs, S.A. Composition de repigmentation capillaire
EP4385515A1 (fr) 2022-12-16 2024-06-19 Bella Aurora Labs, S.A. Composition pour la repigmentation de la peau

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
FR2710340B1 (fr) 1993-09-22 1995-12-15 D Hinterland Lucien Dussourd Dérivés peptidiques de l'alpha-MSH et leur application .
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
FR2753707B1 (fr) * 1996-09-23 1998-12-11 Complexes nucleopeptidiques, compositions cosmetologiques et pharmaceutiques les contenant et utilisations
DE19653736C2 (de) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Kosmetisches Präparat mit Peptidzusatz
GB9808229D0 (en) * 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
FR2781157B1 (fr) * 1998-07-15 2000-08-25 Oreal Composition anti-inflammatoire
GB0012370D0 (en) * 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
ATE385811T1 (de) * 2000-12-19 2008-03-15 Palatin Technologies Inc Identifizierung zielgerichteter faltungsstellen in peptiden und proteinen
EP1441750A4 (fr) * 2001-07-11 2006-10-18 Palatin Technologies Inc Peptides lineaires et cycliques specifiques du recepteur de melanocortine

Also Published As

Publication number Publication date
JP4237067B2 (ja) 2009-03-11
AU2003222347A1 (en) 2003-09-02
CA2474719A1 (fr) 2003-08-07
WO2003064458A2 (fr) 2003-08-07
WO2003064458A3 (fr) 2004-03-25
FR2835528A1 (fr) 2003-08-08
FR2835528B1 (fr) 2004-03-12
KR20040105709A (ko) 2004-12-16
US20050187164A1 (en) 2005-08-25
EP1470157A2 (fr) 2004-10-27
US7268108B2 (en) 2007-09-11
JP2005531496A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2003064458A8 (fr) Derives peptidiques, leur preparation et leur application therapeutique et cosmetique
EP0528312A3 (fr) Peptides cycliques et leur utilisation
WO2002048183A3 (fr) Compositions de cristaux de peptides
AU2003264708A1 (en) Use of aspartic proteases in cosmetics and therapeutics
AU2003264514A1 (en) Wt1 substitution peptides
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
HUP9903530A2 (hu) Új antiangiogén peptidek,azokat kódoló polinukleotidok és eljárások angiogenezis gátlására
WO1996016982A3 (fr) Peptides ultra-selectifs simulant des opioides et leurs utilisations pharmacologiques et therapeutiques
WO2001078503A3 (fr) Genes synthetiques pour gommes vegetales et autres glycoproteines riches en hydroxyprolines
LU91857I2 (fr) Abarelix, optionnellement sous forme de sel pharmaceutiquement acceptable
WO2000012541A3 (fr) Peptides bioactifs
CA2248772A1 (fr) Nouveaux peptides inhibant l'activation du complement
ID21956A (id) Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
AU3458889A (en) Anti-aggregatory peptides
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
EP0749979A3 (fr) Méthode et composition pour traitement de la thrombose
WO2000063246A3 (fr) Composes et procedes de modulation de l'expression genetique par l'intermediaire de la beta-catenine
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
AU2001284419A1 (en) Novel polypeptides and anti-hiv drugs containing the same
WO2002048180A3 (fr) Peptides et/ou proteines ainsi que leur utilisation dans la fabrication d'un medicament therapeutique et/ou preventif
WO2005115174A3 (fr) Conjugues dipeptidiques antagonistes de l’alpha-msh
AU3870195A (en) A novel family of protease inhibitors, and other biologic active substances
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
KR950005320A (ko) 위장 운동 자극 활성을 가지는 폴리펩티드

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2474719

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003564078

Country of ref document: JP

Ref document number: 1020047011955

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003717360

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003717360

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2003 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

WWE Wipo information: entry into national phase

Ref document number: 10503090

Country of ref document: US